Marta Kordalewska

Dr. Marta Kordalewska


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2015 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
WSWiktoria Struck-Lewicka
Wiktoria Struck-Lewicka
MKMarta Kordalewska
Marta Kordalewska
RBRenata Bujak
Renata Bujak
AMArlette Yumba Mpanga
Arlette Yumba Mpanga
MMMarcin Markuszewski
Marcin Markuszewski
MMMichał J. Markuszewski
Michał J. Markuszewski

1 September 2015 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
MKMarta Kordalewska
Marta Kordalewska
MMMichał J. Markuszewski
Michał J. Markuszewski

1 October 2021 in TrAC Trends in Analytical Chemistry
Verified
Journal Article
Open access
DDDanuta Dudzik
Danuta Dudzik
SMSzymon Macioszek
Szymon Macioszek
WSWiktoria Struck-Lewicka
Wiktoria Struck-Lewicka
MKMarta Kordalewska
Marta Kordalewska
MBMagdalena Buszewska-Forajta
Magdalena Buszewska-Forajta
MMMichał J. Markuszewski
Michał J. Markuszewski

20 January 2017 in Bioanalysis
Verified
Journal Article
Closed access
OSOliwia Szerkus
Oliwia Szerkus
WSWiktoria Struck-Lewicka
Wiktoria Struck-Lewicka
MKMarta Kordalewska
Marta Kordalewska
EBEwa Bartosińska
Ewa Bartosińska
RBRenata Bujak
Renata Bujak
DSDanuta Siluk
Danuta Siluk
Aim: The purpose of this work was to develop and validate a rapid and robust LC–MS/MS method for the determination of dexmedetomidine (DEX) in plasma, suitable for analysis of a large number of samples. Method: Systematic approach, Design of Experiments, was applied to optimize ESI source parameters and to evaluate method robustness, therefore, a rapid, stable and cost-effective assay was developed. The method was validated according to US FDA guidelines. LLOQ was determined at 5 pg/ml. The assay was linear over the examined concentration range (5–2500 pg/ml), Results: Experimental design approach was applied for optimization of ESI source parameters and evaluation of method robustness. The method was validated according to the US FDA guidelines. LLOQ was determined at 5 pg/ml. The assay was linear over the examined concentration range (R2 > 0.98). The accuracies, intra- and interday precisions were less than 15%. The stability data confirmed reliable behavior of DEX under tested conditions. Conclusion: A...

25 February 2022 in Cancers
Verified
Journal Article
Open access
PDF file
JJJulia Jacyna
Julia Jacyna
MKMarta Kordalewska
Marta Kordalewska
MAMałgorzata Artymowicz
Małgorzata Artymowicz
MMMarcin Markuszewski
Marcin Markuszewski
MMMarcin Matuszewski
Marcin Matuszewski
MMMichał J. Markuszewski
Michał J. Markuszewski
The incidence of bladder cancer (BCa) has remained high for many years. Nevertheless, its pathomechanism has not yet been fully understood and is still being studied. Therefore, multiplatform untargeted urinary metabolomics analysis has been performed in order to study differences in the metabolic profiles of urine samples collected at three time points: before transurethral resection of bladder tumor (TURBT), the day after the procedure and two weeks after TURBT. Collected samples were analyzed with the use of high-performance liquid chromatography hyphenated with time-of-flight mass spectrometry detection (HPLC-TOF/MS) and gas chromatography coupled with triple quadrupole mass spectrometry detection (GC-QqQ/MS, in a scan mode). Levels of metabolites selected in our previous study were assessed in order to confirm their potential to differentiate the healthy and diseased samples, regardless of the risk factors and individual characteristics. Hippuric acid, pentanedioic acid and uridine confirmed their potential for sample differentiation. Based on the results of statistical analysis for the paired samples (comparison of metabolic profiles of samples collected before TURBT and two weeks after), a set of metabolites belonging to nucleotide metabolism and methylation processes was also selected. Longitudinal studies proved to be useful for the evaluation of metabolic changes in bladder cancer.

1 January 2016 in Talanta
Verified
Journal Article
Closed access
RBRenata Bujak
Renata Bujak
RGRenata Gadzała-Kopciuch
Renata Gadzała-Kopciuch
Alicja NowaczykAlicja Nowaczyk
Alicja Nowaczyk
JRJoanna Raczak-Gutknecht
Joanna Raczak-Gutknecht
MKMarta Kordalewska
Marta Kordalewska
BBBogusław Buszewski
Bogusław Buszewski